Startup Alumis raises $259 million as it prepares for psoriasis trial

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Read the rest…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks